Binex Co Ltd
KOSDAQ:053030
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Binex Co Ltd
Cash from Financing Activities
Binex Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Binex Co Ltd
KOSDAQ:053030
|
Cash from Financing Activities
₩33.2B
|
CAGR 3-Years
118%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Yuhan Corp
KRX:000100
|
Cash from Financing Activities
₩8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-18%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash from Financing Activities
-₩156.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash from Financing Activities
-₩97.2B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash from Financing Activities
₩22.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Cash from Financing Activities
-₩31.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Binex Co Ltd
Glance View
BINEX Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Busan, Busan. The company went IPO on 2001-08-07. The Company’s products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. The company also manufactures bio medicines and raw materials. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Binex Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
33.2B
KRW
Based on the financial report for Dec 31, 2025, Binex Co Ltd's Cash from Financing Activities amounts to 33.2B KRW.
What is Binex Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-5%
Over the last year, the Cash from Financing Activities growth was 11%. The average annual Cash from Financing Activities growth rates for Binex Co Ltd have been 118% over the past three years , -4% over the past five years , and -5% over the past ten years .
